NLS Pharmaceutics AG
NLSP
View Detailed Chart
0.762USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
3.16MMarket Cap
--P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
-66.43%
Year to Date
-63.89%
1 Year
-59.76%
View Detailed Chart
TradingKey Stock Score of NLS Pharmaceutics AG
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered undervalued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NLS Pharmaceutics AG's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
NLS Pharmaceutics AG Highlights
StrengthsRisks
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
Overvalued
The company’s latest PE is -0.47, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 223.48K shares, decreasing 36.60% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
NLS Pharmaceutics AG News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
NLS Pharmaceutics AG Info
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
Ticker SymbolNLSP
CompanyNLS Pharmaceutics AG
CEOZwyer (Alexander)
Websitehttps://nlspharma.com/
FAQs
What is the current price of NLS Pharmaceutics AG (NLSP)?
The current price of NLS Pharmaceutics AG (NLSP) is 0.762.
What is the symbol of NLS Pharmaceutics AG?
The ticker symbol of NLS Pharmaceutics AG is NLSP.
What is the 52-week high of NLS Pharmaceutics AG?
The 52-week high of NLS Pharmaceutics AG is 4.740.
What is the 52-week low of NLS Pharmaceutics AG?
The 52-week low of NLS Pharmaceutics AG is 0.740.
What is the market capitalization of NLS Pharmaceutics AG?
The market capitalization of NLS Pharmaceutics AG is 3.16M.
What is the net income of NLS Pharmaceutics AG?
The net income of NLS Pharmaceutics AG is -4.06M.
Is NLS Pharmaceutics AG (NLSP) currently rated as Buy, Hold, or Sell?
According to analysts, NLS Pharmaceutics AG (NLSP) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of NLS Pharmaceutics AG (NLSP)?
The Earnings Per Share (EPS TTM) of NLS Pharmaceutics AG (NLSP) is -2.629.
Related Instruments
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
